These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31841621)

  • 1. Molecular Dynamics Simulations Applied to Structural and Dynamical Transitions of the Huntingtin Protein: A Review.
    Moldovean SN; Chiş V
    ACS Chem Neurosci; 2020 Jan; 11(2):105-120. PubMed ID: 31841621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into the aggregation mechanism of huntingtin exon 1 protein fragment with different polyQ-lengths.
    Priya SB; Gromiha MM
    J Cell Biochem; 2019 Jun; 120(6):10519-10529. PubMed ID: 30672003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and Dynamics of the Huntingtin Exon-1 N-Terminus: A Solution NMR Perspective.
    Baias M; Smith PE; Shen K; Joachimiak LA; Żerko S; Koźmiński W; Frydman J; Frydman L
    J Am Chem Soc; 2017 Jan; 139(3):1168-1176. PubMed ID: 28085263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
    Chen M; Wolynes PG
    Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Liquid to Solid Phase Transition Underlying Pathological Huntingtin Exon1 Aggregation.
    Peskett TR; Rau F; O'Driscoll J; Patani R; Lowe AR; Saibil HR
    Mol Cell; 2018 May; 70(4):588-601.e6. PubMed ID: 29754822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 17-residue-long N terminus in huntingtin controls stepwise aggregation in solution and on membranes via different mechanisms.
    Pandey NK; Isas JM; Rawat A; Lee RV; Langen J; Pandey P; Langen R
    J Biol Chem; 2018 Feb; 293(7):2597-2605. PubMed ID: 29282287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biophysical Aspect of Huntingtin Protein During polyQ: An In Silico Insight.
    Gopalakrishnan C; Jethi S; Kalsi N; Purohit R
    Cell Biochem Biophys; 2016 Jun; 74(2):129-39. PubMed ID: 27094178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calmidazolium Chloride and Its Complex with Serum Albumin Prevent Huntingtin Exon1 Aggregation.
    Singh V; Deepak RNVK; Sengupta B; Joshi AS; Fan H; Sen P; Thakur AK
    Mol Pharm; 2018 Aug; 15(8):3356-3368. PubMed ID: 29979597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.
    Arndt JR; Chaibva M; Legleiter J
    Biomol Concepts; 2015 Mar; 6(1):33-46. PubMed ID: 25741791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and Characterization of Knock-in Mouse Models Expressing Versions of Huntingtin with Either an N17 or a Combined PolyQ and Proline-Rich Region Deletion.
    André EA; Braatz EM; Liu JP; Zeitlin SO
    J Huntingtons Dis; 2017; 6(1):47-62. PubMed ID: 28211815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glassy dynamics in mutant huntingtin proteins.
    Kang H; Luan B; Zhou R
    J Chem Phys; 2018 Aug; 149(7):072333. PubMed ID: 30134683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models.
    Daldin M; Fodale V; Cariulo C; Azzollini L; Verani M; Martufi P; Spiezia MC; Deguire SM; Cherubini M; Macdonald D; Weiss A; Bresciani A; Vonsattel JG; Petricca L; Marsh JL; Gines S; Santimone I; Marano M; Lashuel HA; Squitieri F; Caricasole A
    Sci Rep; 2017 Jul; 7(1):5070. PubMed ID: 28698602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteostasis of Huntingtin in Health and Disease.
    Koyuncu S; Fatima A; Gutierrez-Garcia R; Vilchez D
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28753941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-atom stability and oligomerization simulations of polyglutamine nanotubes with and without the 17-amino-acid N-terminal fragment of the Huntingtin protein.
    Côté S; Wei G; Mousseau N
    J Phys Chem B; 2012 Oct; 116(40):12168-79. PubMed ID: 22978784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous self-assembly of pathogenic huntingtin exon 1 protein into amyloid structures.
    Trepte P; Strempel N; Wanker EE
    Essays Biochem; 2014; 56():167-80. PubMed ID: 25131594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of mutant Huntingtin aggregates and toxicity by human myeloid leukemia factors.
    Banerjee M; Datta M; Bhattacharyya NP
    Int J Biochem Cell Biol; 2017 Jan; 82():1-9. PubMed ID: 27840155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The possible structural models for polyglutamine aggregation: a molecular dynamics simulations study.
    Zhou ZL; Zhao JH; Liu HL; Wu JW; Liu KT; Chuang CK; Tsai WB; Ho Y
    J Biomol Struct Dyn; 2011 Apr; 28(5):743-58. PubMed ID: 21294586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibril polymorphism affects immobilized non-amyloid flanking domains of huntingtin exon1 rather than its polyglutamine core.
    Lin HK; Boatz JC; Krabbendam IE; Kodali R; Hou Z; Wetzel R; Dolga AM; Poirier MA; van der Wel PCA
    Nat Commun; 2017 May; 8():15462. PubMed ID: 28537272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herp Promotes Degradation of Mutant Huntingtin: Involvement of the Proteasome and Molecular Chaperones.
    Luo H; Cao L; Liang X; Du A; Peng T; Li H
    Mol Neurobiol; 2018 Oct; 55(10):7652-7668. PubMed ID: 29430620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.